Hutchison Chi-Med Blog | Talkmarkets | Page 1
No data available
No data available

People who follow this stock (34)

Latest Posts

About This Stock More About This Stock
Week In Review: Signs Of Life After Coronavirus -- China Biopharma Scores $721 Million In Deals
Article By: ChinaBio® Today
Saturday, April 4, 2020 4:57 PM EDT
Shanghai ZhenGe Biotech, a China CDMO, completed a $51 million Series A financing round led by Shanghai-based healthcare investment firm Lyfe Capita. The company will use the proceeds for additional hires and to expand its Shanghai R&D center
In this article: HCM, BYSI, SNCA
Read
Week In Review: BeiGene's BTK Inhibitor Approved In US And China Approval For PD-1 Expected In Two Months
Article By: ChinaBio® Today
Saturday, November 16, 2019 4:09 PM EDT
Beijing's BeiGene had an outstanding week: its BTK drug, Brukinsa™, was approved for US use to treat mantle cell lymphoma, and its PD-1 candidate is poised for China approval before the end of the year to treat classical Hodgkin’s lymphoma.
In this article: HCM, BGNE, ASLN
Read
Week In Review: Chi-Med Plans $500 Million Hong Kong IPO
Article By: ChinaBio® Today
Saturday, April 20, 2019 4:48 PM EDT
Hutchison China MediTech filed to IPO on the Hong Kong Exchange, following listings in London and on NASDAQ, where it has a market capitalization of over $4 billion. The IPO is expected to raise between $300 million and $500 million.
In this article: RNN, CASI, HCM
Read
Week In Review: BeiGene Forges $1.3 Billion Bi-Specific Antibody Deal With Zymeworks
Article By: ChinaBio® Today
Saturday, December 1, 2018 4:44 PM EDT
BeiGene of Beijing announced cancer drug deals worth up to $1.3 billion with Vancouver's Zymeworks. BeiGene will acquire Asian rights to two bispecific antibodies from Zymeworks and will have rights to three to-be-discovered bispecific candidates.
In this article: LLY, HCM, BGNE, MGNX, ZLAB, TCON, ZYME, BHVN
Read
Week In Review: Innovent's Hong Kong IPO: Raising $422 Million At $2 Billion Valuation
Article By: ChinaBio® Today
Saturday, October 20, 2018 4:16 PM EDT
Innovent Biologics of Suzhou plans to raise $422 million in its Hong Kong IPO at a $2 billion valuation, according to multiple media reports. The company, formed in 2011, struck a major $1 billion collaboration with Lilly in 2015.
In this article: LLY, APDN, CGIX, HCM
Read

PARTNER HEADLINES

Latest Tweets for $HCM

No tweets yet!